APA (7th ed.) Citation

Kapp-Schwoerer, S., Weber, D., Corbacioglu, A., Gaidzik, V. I., Paschka, P., Krönke, J., . . . Döhner, K. (2020). Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: Results from the AMLSG 09-09 trial. Blood, 136(26), . https://doi.org/10.1182/blood.2020005998

Chicago Style (17th ed.) Citation

Kapp-Schwoerer, Silke, et al. "Impact of Gemtuzumab Ozogamicin on MRD and Relapse Risk in Patients with NPM1-mutated AML: Results from the AMLSG 09-09 Trial." Blood 136, no. 26 (2020). https://doi.org/10.1182/blood.2020005998.

MLA (9th ed.) Citation

Kapp-Schwoerer, Silke, et al. "Impact of Gemtuzumab Ozogamicin on MRD and Relapse Risk in Patients with NPM1-mutated AML: Results from the AMLSG 09-09 Trial." Blood, vol. 136, no. 26, 2020, https://doi.org/10.1182/blood.2020005998.